Company news
Decoy Therapeutics Inc. (NASDAQ:DCOY) news
Decoy Therapeutics Inc. news releases on 6ix. Latest, Sep 30, 2026: Decoy Therapeutics to Present at The Small Cap Showcase
Press releases & updates
Decoy Therapeutics to Present at The Small Cap Showcase
September 30, 2026
Decoy Therapeutics to Present at The Small Cap Showcase
September 29, 2026
Decoy Therapeutics Reports Preclinical Data Supporting Once-Weekly Intranasal Dosing for DCOY-CoV Program
September 28, 2026
Decoy Therapeutics Reports Preclinical Data Supporting Once-Weekly Intranasal Dosing for DCOY-CoV Program
September 29, 2026
Decoy Therapeutics, Inc. Issues Correction to Warrant Inducement Transaction Press Release
September 22, 2026
Decoy Therapeutics, Inc. Announces a Warrant Inducement Transaction for $3.85 Million in Gross Proceeds Priced At-The-Market under Nasdaq Rules
September 22, 2026
Decoy Therapeutics Exploring Pan-Filovirus Program via FDA Animal Rule Pathway and Non-Dilutive Funding
September 22, 2026
Decoy Therapeutics to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference
September 8, 2026
Decoy Therapeutics Expands Intellectual Property Portfolio Covering Designable Multi-Antivirals and the IMP³ACT™ Platform
August 3, 2026
Decoy Therapeutics Announces Breakthrough In Vitro Activity Against Ebola Zaire, Expanding D-MAV™ Platform into High Consequence Global Health Threats
July 27, 2026
Decoy Therapeutics Stockholders Elect Patricia Gauthier to Board of Directors
July 15, 2026
Decoy Therapeutics, Inc. Announces Up to $21 Million Private Placement Financing
June 25, 2026
Decoy Therapeutics' CEO to Participate in hVIVO Capital Markets Day in London
June 8, 2026
Decoy Therapeutics Nominates Global Biopharma Executive Patricia Gauthier for Election to Board of Directors
June 3, 2026
Decoy Therapeutics Partners with hVIVO to Advance Lead D-MAV™ Candidate into the Clinic
June 1, 2026
Decoy Therapeutics Names Brad Pentelute, MIT Professor of Chemistry, as Chair of Scientific Advisory Board
May 26, 2026
Decoy Therapeutics to Present at Two Peptide Therapeutics Conferences in Boston
April 27, 2026
Decoy Therapeutics Builds Momentum with Accelerating Execution, Entering a Highly Catalytic Phase with a Clearly Defined Path to Clinical Development of its Antiviral Pipeline
April 9, 2026
Decoy Therapeutics to Participate in Virtual Investor Closing Bell Event Highlighting Business Outlook for 2026
April 6, 2026
Decoy Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
April 2, 2026
Decoy Therapeutics Enters Strategic Partnership with Quantori to Deploy Google Cloud-native Integrated AI-Driven Peptide Design and Molecular Simulation Platform
March 11, 2026
Decoy Therapeutics Announces 1-for-12 Reverse Stock Split
March 4, 2026
Decoy Therapeutics Joins Webull Corporate Connect Service Platform
February 11, 2026
Decoy Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial
February 5, 2026
Decoy Therapeutics Participates in Virtual Investor "What This Means" Segment Highlighting Recently Announced Global Access Commitment Agreement
February 4, 2026
Decoy Therapeutics Reaches Global Access Commitment Agreement to Focus on Development of a Globally Accessible, Scalable Peptide-Conjugate Manufacturing Platform
January 12, 2026